Cargando…
Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy.
Treatment with combined IL-2 and alpha-IFN has resulted in synergistic antitumour efficacy in animal studies. The mechanisms responsible for this synergy remain unclear. In this study, several immune parameters which might be involved in mediating antitumour activity have been monitored serially in...
Autores principales: | von Rohr, A., Ghosh, A. K., Thatcher, N., Stern, P. L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968230/ https://www.ncbi.nlm.nih.gov/pubmed/7678979 |
Ejemplares similares
-
Immunomodulators: interleukins, interferons, and IV immunoglobulin
por: Roelofs, Joris J., et al.
Publicado: (2008) -
A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.
por: Jayson, G. C., et al.
Publicado: (1998) -
Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies.
por: Ghosh, A. K., et al.
Publicado: (1990) -
Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study.
por: Thatcher, N., et al.
Publicado: (1989) -
Thyroiditis after treatment with interleukin-2 and interferon alpha-2a.
por: Pichert, G., et al.
Publicado: (1990)